Yoo et al.1818 Yoo JH, Kim SI, Chung JW, et al. Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. Korean J Anesthesiol. 2018;71:440-6. 2018, Coreia |
100 |
Cirurgia eletiva |
Sevoflurano ou desflurano |
Ap 80 mg + Palono 0,075 mg vs. Palono 0,075 mg |
41 vs. 44 |
41 vs. 44 |
52,4±11,4 vs. 52,1±12,0 |
86,2± 56,1 vs. 89,1± 60,0 |
128,5± 56,1 vs. 131,5± 65,9 |
PCA-IV com fentanil |
Não |
de Morais et al.1919 De Morais LC, Sousa AM, Flora GF, et al. Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial. Acta Anaesthesiol Scand. 2018;62:483-92. 2018, Brasil |
66 |
Procedimentos laparoscópicos abdominais de médio porte ou câncer pélvico |
Propofol anestesia peridural |
Ap 80 mg + Ondan 4-8 mg + dexametasona 4-8 mg vs. placebo + Ondan 4-8 mg + dexametasona 4-8 mg |
34 vs. 32 |
34 vs. 32 |
60,5 (31,87) vs. 50,5 (19,77) |
437,5 (131, 610) vs. 367,5 (145, 600) |
N/A |
tramadol 50 mg + dipirona 2g |
Não |
Ham et al.2020 Ham SY, Shim YH, Kim EH, et al. Aprepitant for antiemesis after laparoscopic gynaecological surgery: a randomised controlled trial. Eur J Anaesthesiol. 2016;33:90-5. 2016, Coreia |
110 |
Cirurgia laparoscópica ginecológica |
Sevoflurano |
Ap 80 mg + Ondan 4 mg vs. placebo + Ondan 4 mg |
55 vs. 55 |
55 vs. 55 |
40 (22-55) vs. 42 (23-61) |
N/A |
N/A |
fentanil iv |
Não |
Kakuta et al.1010 Kakuta N, Kume K, Hamaguchi E, et al. The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study. J Anesth. 2015;29:836-41. 2015, Japão |
38 |
Cirurgia de membro inferior |
Sevoflurano ou desflurano
|
fosaprepitanto 150 mg vs. Ondan 4 mg |
19 vs. 19 |
11 vs. 13 |
61±11 vs. 56±16 |
171±47 vs. 183±67 |
242±55 vs. 264±72 |
diclofenaco de sódio 25mg pentazocina 15mg loxoprofeno 60mg celecoxibe 100mg |
Não |
Soga et al.99 Soga T, Kume K, Kakuta N, et al. Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study. J Anesth. 2015;29:696-701. 2015, Japão |
44 |
Cirurgia ginecológica abdominal |
Sevoflurano, Anestesia peridural com fentanil |
fosaprepitanto 150 mg vs. Ondan 4 mg |
24 vs. 20 |
24 vs. 20 |
52±11 vs. 52±11 |
209±96 vs. 198±82 |
246±94 vs. 239±86 |
anestesia peridural com fentanil |
Não |
Long et al.2121 Long JB, Galdi L, Hentz JG, et al. Prevention of postoperative nausea and vomiting in elective hysterectomy: a prospective, randomized, placebo controlled outcomes trial of aprepitant NK-1 receptor antagonist. Open J Anesthesiol. 2014;4:301-7. 2014, EUA |
94 |
Histerectomia eletiva |
Sevoflurano |
Ap 40 mg + dexametasona 8 mg + Ondan 4 mg vs. placebo + dexametasona 8 mg + Ondan 4 mg |
35 vs. 59 |
35 vs. 59 |
60±12 vs. 53±12 |
153±64 vs. 159±81 |
N/A |
N/A |
Não |
Sinha et al.2222 Sinha AC, Singh PM, Williams NW, et al. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014;24:225-31. 2014, EUA |
124 |
Cirurgia bariátrica |
Sevoflurano ou desflurano |
Ap 80 mg + Ondan 4 mg vs. placebo + Ondan 4 mg |
64 vs. 60 |
42 vs. 39 |
43,09± 12,45 vs. 43,20± 12,70 |
153,05± 43,82 vs. 141,97± 41,80 |
N/A |
fentanil iv ou morfina iv |
Não |
Tsutsumi et al.88 Tsutsumi YM, Kakuta N, Soga T, et al. The effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study. Biomed Res Int. 2014;2014:307025. 2014, Japão |
64 |
Craniotomia eletiva |
Propofol |
fosaprepitanto 150 mg vs. ondansetrona 4 mg |
32 vs. 32 |
17 vs. 21
|
62±10 vs. 58±14 |
366±137 vs. 403±197 |
460±138 vs. 513±166 |
diclofenaco de sódio 25mg pentazocina 15mg loxoprofeno 60mg |
Não |
Moon et al.2323 Moon HY, Baek CW, Choi GJ, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomized trial. BMC Anesthesiol. 2014;14:68. 2014, Coreia |
93 |
Cirurgia ginecológica laparoscópica |
Desflurano |
Ap 40 mg vs. Palono 0,075 mg |
46 vs. 47 |
46 vs. 47 |
37,9±11,1 vs. 37,6±8,0 |
71,5±37,7 vs. 79,2±42,2 |
N/A |
nefopam 20 mg e ACP-IV com fentanil 20 µg.kg-1 automática |
Não |
Lim et al.2424 Lim CS, Ko YK, Kim YH, et al. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting. Korean J Anesthesiol. 2013;64:212-7. 2013, Coreia |
90 |
Cirurgia otorinolaringológica eletiva |
Desflurano |
Ap 125 mg + Ondan 4 mg vs. Ap 80 mg + Ondan 4 mg vs. Ondan 4mg |
26 vs. 28 vs. 24 |
6 vs. 10 vs. 6 |
41±12 vs. 45±12 vs. 42±12 |
55±32 vs. 83±72 vs. 62±32 |
77±31 vs. 105±73 vs. 84±33 |
cetorolaco 30 mg |
Não |
Vallejo et al.2525 Vallejo MC, Phelps AL, Ibinson JW, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg. 2012;129:519-26. 2012, EUA |
150 |
Cirurgia plástica ambulatorial |
Sevoflurano |
Ap 40 mg + Ondan 4 mg vs. placebo + Ondan 4 mg |
75 vs. 75 |
70 vs. 70 |
60,5 (31,87) vs. 50,5 (19,77) |
122,9± 73,3 vs. 117,4± 65,4 |
164,3± 80,1 vs. 153,2± 70,1 |
Fentanil, morfina hidromorfina, oxicodona cetorolaco, meperidina acetaminofeno, ibuprofeno |
Não |
Altorjay et al.2626 Altorjay A, Melson T, Chinachoit T, et al. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg. 2011;146:201-6. 2011, EUA |
456 |
Cirurgia ginecológica laparoscópica |
Sevoflurano |
Caso 50 mg + Ondan 4 mg vs. Placebo + Ondan 4 mg |
227 vs. 229 |
227 vs. 229 |
44,4± 12,19 vs. 44,8± 12,44 |
87,7± 50,39 vs. 92,1± 56,96 |
N/A |
N/A |
Sim |
Lee et al.2727 Lee SJ, Lee SM, Kim SI, et al. The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone. Korean J Anesthesiol. 2012;63:221-6. 2012, Coreia |
84 |
Cirurgia ginecológica |
Desflurano |
Ap 80 mg + Ramo 0,3 mg vs. Ramo 0,3 mg |
42 vs. 42 |
42 vs. 42 |
43,8±8,2 vs. 43,6±10,4 |
113,4± 61,6 vs. 124,1± 48,7 |
145,0± 62,3 vs. 158,8± 48,9 |
PCA-IV com fentanil 21 µg.h-1
|
Não |
Gan et al.2828 Gan TJ, Gu J, Singla N, et al. Rolapitant Investigation Group. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg. 2011;112:804-12. 2011, EUA |
619 |
Laparotomia eletiva |
Sevoflurano ou desflurano ou isoflurano |
Placebo vs. Rola 5 mg vs. Rola 20 mg vs. Rola 70 mg vs. Rola 200 mg vs. Ondan 4 mg |
103 vs. 103 vs. 102 vs. 103 vs. 104 vs. 104 |
103 vs. 103 vs. 102 vs. 103 vs. 104 vs. 104 |
45,8± 10,1 vs. 44,6±10,1 vs. 47,1±12,8 vs. 44,1±10,1 vs. 47,4±10,9 vs. 47,9±12,6 |
209±96 vs. 198±82 |
2,2±1,0 vs. 2,2±1,0 vs. 2,2±1,1 vs. 2,1±1,9 vs. 2,0±0,9 vs. 2,3±1,1 |
N/A |
Sim |
Habib et al.2929 Habib AS, Keifer JC, Borel CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg. 2011;112:813-8. 2011, EUA |
104 |
Craniotomia |
Isoflurano |
Ap 40 mg + dexametasona 10 mg vs. Ondan 4 mg + dexametasona 10 mg |
51 vs. 53 |
28 vs. 30 |
51±13 vs. 48±13 |
180 (130, 223) vs. 179 (128, 213) |
N/A |
fentanil iv oxicodona oral acetaminofeno oral |
Não |
Singla et al.3030 Singla NK, Singla SK, Chung F, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology. 2010;113:74-82. 2010, EUA |
702 |
Laparotomia ginecológica ou colecistec- tomia laparoscópica |
Sevoflurano ou desflurano |
Caso 0 mg + Ondan 4 mg vs. Caso 50 mg + Ondan 4 mg vs. Caso 100 mg + Ondan 4 mg vs. Caso 150 mg + Ondan 4 mg vs. Caso 150 mg |
140 vs. 140 vs. 140 vs. 140 vs. 142 |
140 vs. 140 vs. 140 vs. 140 vs. 142 |
39,3±8,15 vs. 38,1±8,24 vs. 39,5±8,58 vs. 39,3±7,84 vs. 38,5±8,33 |
77,2± 43,28 vs. 77,0± 49,87 vs. 80,5± 47,92 vs. 77,8± 43,74 vs. 79,1± 51,76 |
N/A |
N/A |
Sim |
Diemunsch et al.44 Diemunsch P, Gan TJ, Philip BK, et al. Aprepitant-PONV Protocol 091 International Study Group. Single-dose aprepitant vs. ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007;99:202-11. 2007, EUA |
866 |
Cirurgia abdominal aberta |
Anestesia inalatória |
Ap 40 mg vs. Ap 125 mg vs. Ondan 4mg |
303 vs. 304 vs. 285 |
273 vs. 274 vs. 257 |
46±11 vs. 46±11 vs. 45±11 |
N/A |
2,0±1,0 vs. 1,9±1,0 vs. 1,8±0,9 (h) |
N/A |
Sim |
Gan et al.55 Gan TJ, Apfel CC, Kovac A, et al. Aprepitant-PONV Study Group. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007;104:1082-9. 2007, EUA |
766 |
Cirurgia abdominal aberta |
Anestesia inalatória |
Ap 40 mg vs. Ap 125 mg vs. Ondan 4 mg |
261 vs. 252 vs. 253 |
245 vs. 238 vs. 239 |
46±11,2 vs. 44±9,4 vs. 45±11,2 |
N/A |
2,0±1,0 vs. 2,0±1,0 vs. 2,2±1,2 (h) |
N/A |
Sim |